Interní Med. 2019; 21(1): 32-38 [Med. praxi. 2018;15(5):258-260]

The posibilities of combination pharmacotherapy of arterial hypertension and dyslipidemia in cardiovascular risk reducing

MUDr. Barbora Nussbaumerová, Ph.D.
Centrum preventivní kardiologie, 2. interní klinika LF UK a FN, Plzeň

Hypertension and dyslipidaemia are the most important risk factors of atherosclerotic vascular diseases. Most of hypertensive
patients need combination treatment to reach target blood pressure values. The first line combination contains ACE inhibitors/
AT1 blockres and calcium channel blockers or diuretics. About 70 % of hypertensive patients suffer from dyslipidaemia. Statin
therapy must be taken in account, according to the total cardiovascular risk. Fixed combinations improve compliance and efficacy
of the treatment. Antihypertensive drugs, hypolipidemics and also the combination of both are available in fixed combinations.

Keywords: arterial hypertension, dyslipidemia, compliance, fixed combination

Published: February 21, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nussbaumerová B. The posibilities of combination pharmacotherapy of arterial hypertension and dyslipidemia in cardiovascular risk reducing. Interní Med. 2019;21(1):32-38.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cífková R, Škodová Z, Bruthans J, et al. Longitudinal trends in cardiovascular mortality and blood pressure levels, prevalence, awareness, treatment, and control of hypertension in the Czech population from 1985 to 2007/2008. J Hypertens 2010; 28(11): 2196-2203. Go to original source... Go to PubMed...
    2. Kettani FZ, Dragomir A, Côté R, et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke 2009; 40(1): 213-220. Go to original source... Go to PubMed...
    3. Peters R, Beckett N, Forrete F, et al. Incident dementia and blood pressure lowering in the HYpertension in Very Elderly Trial cognitive function assement. Lance Neurol 2008; 7(8): 683-689. Go to original source... Go to PubMed...
    4. Mancia G, Laurent S, Agabiti-Rosei L, et al. Reappraisal of European guidelines on hypertension management: a European Society of hypertension Task Force dokument. J Hypertens 2009; 27(11): 2121-2158. Go to original source... Go to PubMed...
    5. Lonn EM, Bosch J, Lopez-Jaramiloo P, et al. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med 2016; 374: 2009-2020. Go to original source... Go to PubMed...
    6. Bramlage P, Bohm M, Volpe M, et al. A global perspective on blood pressure treatment and control in a referred cohort of hypertensive patiens. J Clin Hypertens 2010; 12(9): 666-677. Go to original source... Go to PubMed...
    7. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122(3): 290-300. Go to original source... Go to PubMed...
    8. Widimský J jr., Filipovský J, Ceral J, et al. Diagnostické a léčebné postupy u arteriální hypertenze - verze 2017. Doporučení České společnosti pro hypertenzi. Hypertenze & kardiovaskulární prevence 2018; 7(Suppl.): 2-22.
    9. Williams B, Mancia G, Spiering W, et al. Authors/Task Force Members: 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens 2018; 36: 1953-2041. Go to original source... Go to PubMed...
    10. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): multicentre randomised controlled trial. Lancet 2005; 366(9489): 895-906. Go to original source... Go to PubMed...
    11. Jamerson K, Weber MA, Bakris GL. Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients. N Engl J Med 2008; 359: 2417-2428. Go to original source... Go to PubMed...
    12. Patel A. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370(9590): 829-840. Go to original source... Go to PubMed...
    13. Dahlöf B, Devereux RB, Kjeldsen SE, et al. LIFEStudy Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002 Mar 23; 359(9311): 995-1003. Go to original source... Go to PubMed...
    14. Matsuzaki M, Ogihara T, Umemoto S. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens. 2011; 29(8): 1649-1659. Go to original source... Go to PubMed...
    15. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120(8): 713-719. Go to original source... Go to PubMed...
    16. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes trial-Lipid Lowering Arm (ASCOTT-LLA): a multicenter randomised controlled trial. Lancet 2003; 361: 1149-1158. Go to original source... Go to PubMed...
    17. Sever PS, Poulter NR, Dahlöf B, et al. The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. Eur Heart J 2008; 29: 499-508. Go to original source... Go to PubMed...
    18. Janský P, et al. 2016 ESC/EAS Guidelines for the management of dyslipidaemias: Summary of the document prepared by the Czech Society of Cardiology, Cor et Vasa 2017; 59: e389-e415. Dostupné z: http://www.sciencedirect.com/science/article/pii/S0010865017300371 Go to original source...
    19. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal 2016; 37: 2999-3058. Dostupné z: https://www.escardio.org/static_file/escardio/Guidelines/publications/DYSLIPguidelinesdyslipidemias-FT.pdf Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.